3073-59-4
Chemical Structure
Hexamethylene bisacetamide
Synonym(s): HMBA
- CAS No.: 3073-59-4
- Formula:C10H20N2O2
- Molecular Weight:200.28
IUPAC Name: N,N'-(hexane-1,6-diyl)diacetamide
InChIKey: BNQSTAOJRULKNX-UHFFFAOYSA-N
SMILES: CC(NCCCCCCNC(C)=O)=O
Biological Activity: Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Hexamethylene bisacetamide | 99.56% | Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Hexamethylene bisacetamide (Standard) | ≥98% | Hexamethylene bisacetamide (Standard) is the analytical standard of Hexamethylene bisacetamide. This product is intended for research and analytical applications. Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.82
HY-B1259R6-Acetamidohexanoic acid (Standard) -
Similarity Score 0.79
HY-W175189N,N'-(Pentane-1,5-diyl)bis(2-chloroacetamide) -
Similarity Score 0.79
HY-113056ARN1-Acetylspermidine hydrochloride (Standard) -
Similarity Score 0.79
HY-113253ARN8-Acetylspermidine dihydrochloride (Standard) -
Similarity Score 0.79
HY-W3288415-Acetamidopentanoic acid -
Similarity Score 0.78
HY-101403AMonoacetylcadaverine hydrochloride -
Similarity Score 0.78
HY-101403N-(5-Aminopentyl)acetamide -
Similarity Score 0.78
HY-163788C5-CONH-C2-N-CH3 -
Similarity Score 0.78
HY-W7482852-Octanamidoacetic acid-13C2,15N -
Explore the MedChemAI to find more analogs
References
- [1]. Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76(8):2376-83. [Content Brief]
- [2]. Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84(5):831-8. [Content Brief]
- [3]. Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67. [Content Brief]
- [4]. Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32(5):791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ [Content Brief]
- [5]. Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15(12):e18024. [Content Brief]
